Veru Stock News

Veru Inc (VERU) shares closed today at 0.9% above its 52 week low of $5.41, giving the company a market cap of $436M. The stock is currently down 7.3% year-to-date, down 42.8% over the past 12 months, and up 440.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 19.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 68.9% The company's stock price performance over the past 12 months lags the peer average by 129.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 196.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Veru Inc (VERU) shares closed today at 0.9% above its 52 week low of $5.41, giving the company a market cap of $444M. The stock is currently down 5.6% year-to-date, down 39.8% over the past 12 months, and up 450.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 19.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.8% lower than its 5-day moving average, 9.9% lower than its 20-day moving average, and 30.7% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 107.5% The company's stock price performance over the past 12 months lags the peer average by 125.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 189.7% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Veru Inc (VERU) shares closed 1.7% lower than its previous 52 week low, giving the company a market cap of $490M. The stock is currently up 4.1% year-to-date, down 23.9% over the past 12 months, and up 544.8% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 56.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -866.5% The company's stock price performance over the past 12 months lags the peer average by 74.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 216.6% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,

MIAMI, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, to

Veru Inc. (NASDAQ:VERU) with the stream of 0.32% also noticed, India Avino Silver & Gold Mines Ltd. (AMEX:ASM) encountered a rapid change of 3.41% in the last hour of Thursdays The post Exceptional Stock in Review: Veru Inc. (NASDAQ:VERU), Avino Silver & Gold Mines Ltd. (AMEX:ASM) appeared first on Stocks Equity .

Selective Wealth Management Inc. acquired a new position in shares of Veru Inc. (NASDAQ:VERU) in the 3rd quarter, Holdings Channel reports. The fund acquired 10,000 shares of the companys stock, valued at approximately $85,000. Several other large investors also recently modified their holdings of VERU. Federated Hermes Inc. acquired a new position in Veru in []

Veru Inc. (NASDAQ:VERU) shares saw unusually-strong trading volume on Monday . Approximately 56,802 shares changed hands during mid-day trading, a decline of 97% from the previous sessions volume of 1,844,395 shares.The stock last traded at $6.63 and had previously closed at $6.25. Several analysts recently commented on VERU shares. Brookline Capital Management restated a buy []

This article was originally published on TipRanks.com Veru, Inc. The post FDA Approves Veru’s ENTADFI Oral Capsule appeared first on Smarter Analyst .

(RTTNews) - Today''s Daily Dose brings you news about the clinical hold imposed by the FDA on Merck''s trials; CSL Limited evincing interest for a Swiss based biotech, Atara''s ALLELE trial results, FDA approval of Veru''s ENTADFI and the Leukemia & Lymphoma Society''s findings regarding the need for a third primary dose of mRNA COVID-19 vaccine for…

--ENTADFI (Finasteride and Tadalafil) Capsules to Treat Benign Prostatic Hyperplasia-- --Commercialization Will Start Early Calendar Year 2022--

Morgan Stanley decreased its position in Veru Inc. (NASDAQ:VERU) by 61.4% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 400,279 shares of the companys stock after selling 636,898 shares during the period. Morgan Stanleys holdings in Veru were worth $3,231,000 at the end of the most []

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate c

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer, today announced that human preclinical data will be presented demonstrating that enobosarm treatment alone as well as in combination with a CDK4/6 inhibitor increased androgen receptor (AR) expression resulting in the synergistic suppression of breast cancer cell and tumor models that are resistant to CDK4/6 inhibitors and estrogen blocking agents. Enobosarm is an oral, first-in-class, selective androgen receptor targeted agonist for the androgen receptor, a tumor suppressor, being evaluated in Phase 3 clinical studies to treat AR+ER+HER2- metastatic breast cancer without unwanted masculinizing side effects. The presentation was selected as a spotlight presentation at the San Antonio Breast Cancer Symposium being held December 07-10, 2021, in San Antonio, TX.